$HOTH is our low-float Nasdaq listed biotech Breakout alert $10
=====================
HOTH (Hoth Therapeutics, Inc.)
Float: 3.86M
Alert Price: $6.57
Target Price: $10.00
Chart Analysis
Investor Presentation
Website | Recent News
========================
Members,
We hope you enjoyed the easy double-digit gains that today's trade idea delivered.
You'll be happy to know that we have already identified an even more exciting trade idea for you.
Please turn your immediate attention to HOTH (Hoth Therapeutics, Inc.)
HOTH is the perfect candidate for a monster move tomorrow.
The Company:
Has a tight float of 3.86M
Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News)
Is listed on the Nasdaq Exchange (High Liquidity)
Suffered a sharp pullback today (Perfect "Buy the Dip" Opportunity")
Has a $10 Price Target (+52% Upside)
HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88.
HOTH's recent pullback has created the ultimate buy the dip opportunity for traders.
We all know how explosive these small-cap biotech stocks can be...
Any type of market friendly news could trigger a huge move in share price.
Today we watched RWLK jump over +200% on positive FDA news.
With HOTH's tiny 3.2M float, any type of market friendly news could send shares soaring.
HOTH also has several bullish catalysts on the horizon that have us confident that its $10 price-target is well within reach.
Atopic Dermatitis is a large and growing market
Affects more than 32 million patients in the US
10 20% of all pediatric patients suffer from Atopic Dermatitis
Need for new, differentiated therapies
HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups
Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019
Study will test efficacy, safety, and ease of use
On target to complete Phase 2 clinical trial by end of Q1 2020
As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline.
Can you imagine how high HOTH shares could go if it were to receive FDA approval?
Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains.
About HOTH Therapeutics
Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.
Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.
They intend to explore the use of the BioLexa™ Platform for the treatment of atopic dermatitis, or eczema.
They also intend to explore the use of the BioLexa Platform™ in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. They believe that the BioLexa Platform™s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection.
Finally, they intend to explore the use of the BioLexa Platform™ in connection with diabetic foot ulcers. We believe that the BioLexa Platform™s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus.
Genetic Marker License
Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology.
Company Highlights:
Unique small cap specialty pharma investment opportunity with multiple shots on goal and capital business model.
Multi-billion market opportunity with large unmet need for both the Company’s primary and secondary asset.
Proprietary platform technology which combines two existing approved drugs enabling reliance on existing safety data for those drugs.
Proprietary BioLexa platform technology which combines two existing approved drugs enabling reliance on existing safety data.
VNLG 152 strong pre-clinical data in acne and psoriasis.
Strong IP Portfolio, including licenses to patents and trademarks.
Signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Experienced management team, board of directors and scientific advisors with proven drug development experience.
Recent Milestones
Entered into licensing agreement with the University of Maryland and Isoprene Pharmaceuticals. (March 2019)
Began pilot study in chronic diabetic ulcers at Mass General Vaccine and Immunotherapy Center (March 2019)
Announced Closing of Initial Public Offering.
Latest News
Hoth and Zylö to use new topical application of an endocannabinoid, anandamide (AEA), in nanoparticles
NEW YORK, May 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; www.zylotherapeutics.com/
Scientists at Einstein College of Medicine recently demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. This work reinforces and highlights the utility of targeting the endocannabinoid system for autoimmune rheumatic diseases.
The work at Einstein supports the thesis that AEA loaded into Z-pods™ improves drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation.
According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.
"Management is extremely pleased to partner with Zylö Therapeutics, enhancing our portfolio of unique treatments for patients suffering from various dermatological related ailments," stated, Mr. Robb Knie, CEO of Hoth Therapeutics. "Zylö's initial work shows significant promise in combating Cutaneous Lupus Erythematosus, and we look forward to working with them in order to bring this treatment to market."
"We are thrilled to partner with Hoth, a company that is committed to innovative solutions and partnerships to develop treatments for diseases with a high unmet clinical need, such as lupus," said Scott Pancoast, CEO of Zylö. "As we work with the Hoth team to advance AEA-loaded Z-pods through the next stages of development, we expect to further demonstrate the important role that our patented Z-pod delivery system plays in improving treatment outcomes."
The term sheet is non-binding and neither party thereto shall have any obligation to consummate a transaction of any kind until such time as the parties have entered into a mutually agreeable definitive agreement. There can be no assurance that any such definitive agreement will be entered into or that the transaction will be completed on the terms set forth in the term sheet, or at all.
Market Outlook:
Atopic dermatitis market predicted to grow $7.2B in 2017 to $24B by end of 2027.
It affects more than 32 million patients in the US.
Diabetic Foot Ulcers affect approximately 9.1-26.1M people worldwide, about 19 34% of people with diabetes are likely to be affected.
Nearly 7.5 million people are affected by psoriasis in the US alone and represent about 2% of the population with approximately 100,000 new cases reported each year.*
60 million people suffering from all grades of acne in the US, 20% of which is severe enough to result in facial scarring.
Technical Analysis
As we stated above, with HOTH's tiny 3.2M float, any type of market friendly news could send its shares soaring.
HOTH suffered a sharp pullback today creating the perfect "Buy the Dip" opportunity.
HOTH has plenty of room to the upside, a move back to its 52-week high of $13.88 would net traders over +100% in profit from today's alert price.
We've done our very own chart analysis and see the potential for a move to $13.82.
HOTH has shown very little resistance once it breaks $8.80.
We see a strong uptrend, and an impulse to move higher.
This is a potential triple-digit gain opportunity
The Bottom-Line
We love these low-float bio-tech alerts.
They have the tendency to breakout faster and bigger than any other sector.
HOTH has the potential to be the next RWLK, and could lead the NASDAQ in gains tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars by Source 4 Communications LLC to conduct a two-day investor relations advertising and marketing campaign for HOTH. . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
HOTH (Hoth Therapeutics, Inc.)
Float: 3.86M
Alert Price: $6.57
Target Price: $10.00
Chart Analysis
Investor Presentation
Website | Recent News
========================
Members,
We hope you enjoyed the easy double-digit gains that today's trade idea delivered.
You'll be happy to know that we have already identified an even more exciting trade idea for you.
Please turn your immediate attention to HOTH (Hoth Therapeutics, Inc.)
HOTH is the perfect candidate for a monster move tomorrow.
The Company:
Has a tight float of 3.86M
Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News)
Is listed on the Nasdaq Exchange (High Liquidity)
Suffered a sharp pullback today (Perfect "Buy the Dip" Opportunity")
Has a $10 Price Target (+52% Upside)
HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88.
HOTH's recent pullback has created the ultimate buy the dip opportunity for traders.
We all know how explosive these small-cap biotech stocks can be...
Any type of market friendly news could trigger a huge move in share price.
Today we watched RWLK jump over +200% on positive FDA news.
With HOTH's tiny 3.2M float, any type of market friendly news could send shares soaring.
HOTH also has several bullish catalysts on the horizon that have us confident that its $10 price-target is well within reach.
Atopic Dermatitis is a large and growing market
Affects more than 32 million patients in the US
10 20% of all pediatric patients suffer from Atopic Dermatitis
Need for new, differentiated therapies
HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups
Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019
Study will test efficacy, safety, and ease of use
On target to complete Phase 2 clinical trial by end of Q1 2020
As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline.
Can you imagine how high HOTH shares could go if it were to receive FDA approval?
Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains.
About HOTH Therapeutics
Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.
Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.
They intend to explore the use of the BioLexa™ Platform for the treatment of atopic dermatitis, or eczema.
They also intend to explore the use of the BioLexa Platform™ in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. They believe that the BioLexa Platform™s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection.
Finally, they intend to explore the use of the BioLexa Platform™ in connection with diabetic foot ulcers. We believe that the BioLexa Platform™s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus.
Genetic Marker License
Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology.
Company Highlights:
Unique small cap specialty pharma investment opportunity with multiple shots on goal and capital business model.
Multi-billion market opportunity with large unmet need for both the Company’s primary and secondary asset.
Proprietary platform technology which combines two existing approved drugs enabling reliance on existing safety data for those drugs.
Proprietary BioLexa platform technology which combines two existing approved drugs enabling reliance on existing safety data.
VNLG 152 strong pre-clinical data in acne and psoriasis.
Strong IP Portfolio, including licenses to patents and trademarks.
Signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Experienced management team, board of directors and scientific advisors with proven drug development experience.
Recent Milestones
Entered into licensing agreement with the University of Maryland and Isoprene Pharmaceuticals. (March 2019)
Began pilot study in chronic diabetic ulcers at Mass General Vaccine and Immunotherapy Center (March 2019)
Announced Closing of Initial Public Offering.
Latest News
Hoth and Zylö to use new topical application of an endocannabinoid, anandamide (AEA), in nanoparticles
NEW YORK, May 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; www.zylotherapeutics.com/
Scientists at Einstein College of Medicine recently demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. This work reinforces and highlights the utility of targeting the endocannabinoid system for autoimmune rheumatic diseases.
The work at Einstein supports the thesis that AEA loaded into Z-pods™ improves drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation.
According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.
"Management is extremely pleased to partner with Zylö Therapeutics, enhancing our portfolio of unique treatments for patients suffering from various dermatological related ailments," stated, Mr. Robb Knie, CEO of Hoth Therapeutics. "Zylö's initial work shows significant promise in combating Cutaneous Lupus Erythematosus, and we look forward to working with them in order to bring this treatment to market."
"We are thrilled to partner with Hoth, a company that is committed to innovative solutions and partnerships to develop treatments for diseases with a high unmet clinical need, such as lupus," said Scott Pancoast, CEO of Zylö. "As we work with the Hoth team to advance AEA-loaded Z-pods through the next stages of development, we expect to further demonstrate the important role that our patented Z-pod delivery system plays in improving treatment outcomes."
The term sheet is non-binding and neither party thereto shall have any obligation to consummate a transaction of any kind until such time as the parties have entered into a mutually agreeable definitive agreement. There can be no assurance that any such definitive agreement will be entered into or that the transaction will be completed on the terms set forth in the term sheet, or at all.
Market Outlook:
Atopic dermatitis market predicted to grow $7.2B in 2017 to $24B by end of 2027.
It affects more than 32 million patients in the US.
Diabetic Foot Ulcers affect approximately 9.1-26.1M people worldwide, about 19 34% of people with diabetes are likely to be affected.
Nearly 7.5 million people are affected by psoriasis in the US alone and represent about 2% of the population with approximately 100,000 new cases reported each year.*
60 million people suffering from all grades of acne in the US, 20% of which is severe enough to result in facial scarring.
Technical Analysis
As we stated above, with HOTH's tiny 3.2M float, any type of market friendly news could send its shares soaring.
HOTH suffered a sharp pullback today creating the perfect "Buy the Dip" opportunity.
HOTH has plenty of room to the upside, a move back to its 52-week high of $13.88 would net traders over +100% in profit from today's alert price.
We've done our very own chart analysis and see the potential for a move to $13.82.
HOTH has shown very little resistance once it breaks $8.80.
We see a strong uptrend, and an impulse to move higher.
This is a potential triple-digit gain opportunity
The Bottom-Line
We love these low-float bio-tech alerts.
They have the tendency to breakout faster and bigger than any other sector.
HOTH has the potential to be the next RWLK, and could lead the NASDAQ in gains tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars by Source 4 Communications LLC to conduct a two-day investor relations advertising and marketing campaign for HOTH. . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.